MSOLU Alzheimer's Disease DNA Test
Take Control of Cognitive Health – ApoE Gene Test
Genetics cannot be changed, but risk can be managed.
For individuals over 30, recurring memory decline may signal more than stress. Alzheimer’s disease develops gradually, often after years of ignored warning signs.
ApoE genetic testing provides a precise assessment of inherited risk. ApoE is the most validated genetic marker associated with Alzheimer’s disease. Identifying your genotype (ε2, ε3, ε4) offers a clear framework for proactive brain health planning.
This test supports evidence‑based decisions, reduces risk, and safeguards long‑term wellbeing.
For individuals over 30, recurring memory decline may signal more than stress. Alzheimer’s disease develops gradually, often after years of ignored warning signs.
ApoE genetic testing provides a precise assessment of inherited risk. ApoE is the most validated genetic marker associated with Alzheimer’s disease. Identifying your genotype (ε2, ε3, ε4) offers a clear framework for proactive brain health planning.
This test supports evidence‑based decisions, reduces risk, and safeguards long‑term wellbeing.
Analytical Accuracy > 99%
Non-invasive, Safe & Easy
Painless Oral Swab Sampling
Structured 1-2-3 Approach
1
1
Risk Identification
A single test establishes genetic profile and risk rating. Data is the foundation for action.
2
2
Proactive Management
Quantify & Monitor
Cadence checks of p-Tau217, cholesterol, glucose, and inflammatory markers, combined with interval cognitive health tracking.
Lifestyle Intervention
Implement targeted lifestyle adjustments and cognitive training.
Financial Security
Establish financial and legal protections early.
3
3
Timely Medical Intervention
Therapies show greatest benefit in early stages. Testing now ensures readiness to act within the optimal treatment window.
Early detection secures future options.
Early detection secures future options.
Sample Collection
Please follow the steps below to collect your sample ( 2 samples are required ).
STEP 1
Please rinse your mouth with drinking water 30 minutes before sampling. Keep your mouth clean and do not eat, drink, or smoke during this period.
STEP 2
Press the swab against the inside of the left cheek and rotate 10-15 times to collect as much oral cell as possible.
STEP 3
Place the swab tip into the tube; break off the handle at the breakpoint and securely tighten the tube cap.
STEP 4
Press the 2nd swab against the inside of the right cheek and rotate 10-15 times to collect as much oral cell as possible.
STEP 5
Place the swab tip into the 2nd tube to complete the 2nd sampling.
STEP 1
STEP 2
STEP 3
STEP 4
STEP 5
Professional Report within15-21working days
(from the date the laboratory receives a qualified sample)
MSOLU Test Kit Features
Fully equipped with simple tools and comprehensive guidance for accuracy
Designed for Medical Endorsement and Referral
Accredited local laboratory designated for sample processing and reporting.
Recommended for
Individuals showing signs of memory or cognitive decline
Those with family history of Alzheimer's or dementia
Patients with chronic cardiovascular disease or lipid disorders
For individuals engaged in preventive health planning
About Alzheimer's Disease
Alzheimer’s Disease Overview
Alzheimer’s disease is a progressive, irreversible neurodegenerative disorder. Early‑onset cases (before age 65) account for up to 9%¹ worldwide. In Asia, cases have risen by more than 250%² in the past three decades.
No Definitive Cure
Current therapies slow progression but do not cure3,4. Prevention and early intervention remain the most effective strategies.
Proactive Risk Assessment
Each person carries two ApoE genes:
One ApoE ε4 allele increases lifetime risk 2–4 times⁵.
Two ApoE ε4 alleles increase risk 8–12 times⁵, with approximately 60% developing Alzheimer’s disease by age 85⁶.
Results are not diagnostic but serve as an early warning, enabling preventive measures before symptoms emerge.
One ApoE ε4 allele increases lifetime risk 2–4 times⁵.
Two ApoE ε4 alleles increase risk 8–12 times⁵, with approximately 60% developing Alzheimer’s disease by age 85⁶.
Results are not diagnostic but serve as an early warning, enabling preventive measures before symptoms emerge.
(1)https://www.who.int/news-room/fact-sheets/detail/dementia
(2)https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1583339/full
(3)https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval
(4)https://www.medscape.com/viewarticle/more-evidence-lowering-amyloid-clinically-beneficial-early-2025a1000s05
(5)https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-disease/in-depth/alzheimers-genes/art-20046552
(6)https://www.nia.nih.gov/news/study-defines-major-genetic-form-alzheimers-disease
(2)https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1583339/full
(3)https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval
(4)https://www.medscape.com/viewarticle/more-evidence-lowering-amyloid-clinically-beneficial-early-2025a1000s05
(5)https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-disease/in-depth/alzheimers-genes/art-20046552
(6)https://www.nia.nih.gov/news/study-defines-major-genetic-form-alzheimers-disease
Contact Us
+85246446021
Whatsapp
Our Partners
